Posts

FDA clears Curium’s BEXLUTRY, a Lutathera-equivalent radioligand therapy

on

Novartis board faces investor scrutiny after M&A misfires and R&D setbacks

on

Major Novartis shareholder calls for board shake-up after trial setbacks

on

Major Novartis shareholder calls for board shake-up after trial setbacks

on

Novartis’s Triple Clinical Setback Hits Shares and Weighs on Pharma Peers

on

Major Novartis shareholder calls for board shake-up after trial setbacks

on

Major Novartis shareholder calls for board shake-up after trial setbacks

on

Novartis’s Pelacarsen Fails to Reduce Cardiovascular Risk in Phase 3 Trial

on

Novartis stock drops after Avidity centerpiece fails Phase 3 trial

on

Novartis drops after Avidity-acquired muscle-drug trial miss

on

Novartis may cut around 130 jobs in Switzerland while relocating biologics production

on

Novartis’ Rhapsido shows positive Phase 3 MS results, intensifying Roche competition

on

Novartis Selects Alteogen Technology in Potential $3.22 Billion Subcutaneous-Drug Deal

on

Novartis’ Rhapsido scores two Phase III wins in relapsing MS

on

Novartis and BMS pause autoimmune CAR-T trials after serious immune-related events

on

Novartis keeps its IL-6 bet alive after Novo Nordisk trial failure

on

Lp(a): Why biotech is betting on the “diabolical” molecule

on

AbbVie, Novartis and Bristol Myers Squibb Sue Illinois Over 340B Contract Pharmacy Law

on

Novartis' Pluvicto leaps ahead into earlier manifestation of prostate cancer

on

Novartis drops phase 2 radioligand therapy, but CEO’s commitment to the modality unchanged

on